
H.B. 258 - Medicaid Drug Utilization Amendments - As Amended

Fiscal Note

2008 General Session

State of Utah

State Impact

Enactment of this legislation will require an appropriation of \$23,000 from the General Fund and \$56,000 in Federal Funds for FY 2009. In FY 2010, the costs of this legislation will be \$25,300 from the General Fund and \$61,900 in Federal Funds.

	FY 2008	FY 2009	FY 2010	FY 2008	FY 2009	FY 2010
	<u>Approp.</u>	<u>Approp.</u>	<u>Approp.</u>	<u>Revenue</u>	<u>Revenue</u>	<u>Revenue</u>
General Fund	\$0	\$25,300	\$25,300	\$0	\$0	\$0
General Fund, One-Time	\$0	(\$2,300)	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$56,000	\$61,900	\$0	\$0	\$0
Total	<u>\$0</u>	<u>\$79,000</u>	<u>\$87,200</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>

Individual, Business and/or Local Impact

The increased costs to the state and the amounts currently paid for generic immunosuppressive drugs affected by this legislation would now be paid to brand name manufacturers instead of generic drug manufacturers.

Enactment of this bill likely will not result in direct, measurable costs and/or benefits for individuals or local governments.